Cytisine, the world's oldest smoking cessation aid: Growing evidence for its use as an affordable treatment globally

BMJ (Online)

Volumn 347, Issue 7923, 2013, Pages

  Prochaska, Judith J ^a   Das, Smita ^b   Benowitz, Neal L ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; CYTISINE; NICOTINIC RECEPTOR ALPHA4BETA2; NORTRIPTYLINE; PLACEBO; VARENICLINE;

CONTROLLED CLINICAL TRIAL (TOPIC); DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DYSPEPSIA; EDITORIAL; HUMAN; NAUSEA; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SMOKING CESSATION; STOMACH PAIN; TOBACCO DEPENDENCE; XEROSTOMIA;

ALKALOIDS; AZOCINES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NICOTINE; QUINOLIZINES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84883759957     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5198     Document Type: Editorial

References (15)

1. Husemann A, Marme W. Zeitschr f Chemie 1865;1:161.
2. Dale HH, Laidlaw PP. The physiological action of cytisine, the active alkaloid of laburnum (Cytisus laburum). J Pharmacol Exp Ther 1912;3:205-21.
3. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax [forthcoming].
4. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-200.
5. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103.
6. WHO. WHO report on the global tobacco epidemic, 2013. Enforcing bans on tobacco advertising, promotion and sponsorship. www.who.int/tobacco/global- report/2013/en/.
7. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2012;1:CD003999.
8. WHO, Framework Convention on Tobacco Control. Global progress report on implementation of the WHO Framework Convention on Tobacco Control. 2012. www. who.int/fctc/reporting/2012-global-progress-report-en.pdf.
9. Adams CP, Brantner VV. Spending on new drug development 1. Health Econ 2010;19:130-41.
10. Aveyard P, West R. Cytisine and the failure to market and regulate for human health. Thorax [forthcoming].
11. Pfizer. 2011 financial report. www.pfizer.com/files/annualreport/2011/ financial/financial2011. pdf.
12. Yohannes D, Procko K, Lebel LA, Fox CB, O'Neill BT. Deconstructing cytisine: the syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorgan Medicinal Chem Letters 2008;18:2316-9. (Pubitemid 351442905)
13. Perfetti TA. Preparation of iodocytisine and iodolobeline. Legacy Tobacco Products Library, 1986. http://legacy.library.ucsf.edu/tid/qkk93i00/pdf.
14. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012;44:588-97.
15. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:CD000146.